Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 3
2023 24
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Non-coding RNA-based therapeutics in cancer therapy: An emphasis on Wnt/β-catenin control.
Taheriazam A, Bayanzadeh SD, Heydari Farahani M, Mojtabavi S, Zandieh MA, Gholami S, Heydargoy MH, Jamali Hondori M, Kangarloo Z, Behroozaghdam M, Khorrami R, Sheikh Beig Goharrizi MA, Salimimoghadam S, Rashidi M, Hushmandi K, Entezari M, Hashemi M. Taheriazam A, et al. Among authors: zandieh ma. Eur J Pharmacol. 2023 Jul 15;951:175781. doi: 10.1016/j.ejphar.2023.175781. Epub 2023 May 11. Eur J Pharmacol. 2023. PMID: 37179043 Review.
PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.
Rezaei S, Nikpanjeh N, Rezaee A, Gholami S, Hashemipour R, Biavarz N, Yousefi F, Tashakori A, Salmani F, Rajabi R, Khorrami R, Nabavi N, Ren J, Salimimoghadam S, Rashidi M, Zandieh MA, Hushmandi K, Wang Y. Rezaei S, et al. Among authors: zandieh ma. Eur J Pharmacol. 2023 Sep 15;955:175909. doi: 10.1016/j.ejphar.2023.175909. Epub 2023 Jul 23. Eur J Pharmacol. 2023. PMID: 37490949 Review.
Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.
Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, Taheriazam A, Alexiou A, Papadakis M, Tan SC. Hashemi M, et al. Among authors: zandieh ma. Cell Mol Biol Lett. 2023 Apr 21;28(1):33. doi: 10.1186/s11658-023-00438-9. Cell Mol Biol Lett. 2023. PMID: 37085753 Free PMC article. Review.
Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy.
Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, Karimi F, Samaei SS, Rezaee A, Rahmanian P, Khorrami R, Salimimoghadam S, Nabavi N, Zou R, Sethi G, Rashidi M, Hushmandi K. Zandieh MA, et al. Biomed Pharmacother. 2023 Oct;166:115283. doi: 10.1016/j.biopha.2023.115283. Epub 2023 Aug 9. Biomed Pharmacother. 2023. PMID: 37567073 Free article. Review.
Progress in targeting PTEN/PI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions.
Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, Ahmadi F, Salimimoghadam S, Aref AR, Zandieh MA, Entezari M, Taheriazam A, Hushmandi K. Hashemi M, et al. Among authors: zandieh ma. Biomed Pharmacother. 2023 Feb;158:114204. doi: 10.1016/j.biopha.2022.114204. Epub 2023 Jan 4. Biomed Pharmacother. 2023. PMID: 36916430 Free article. Review.
Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery.
Hashemi M, Aparviz R, Beickzade M, Paskeh MDA, Kheirabad SK, Koohpar ZK, Moravej A, Dehghani H, Saebfar H, Zandieh MA, Salimimoghadam S, Rashidi M, Taheriazam A, Entezari M, Samarghandian S. Hashemi M, et al. Among authors: zandieh ma. Biomed Pharmacother. 2023 Dec 31;169:115927. doi: 10.1016/j.biopha.2023.115927. Epub 2023 Nov 24. Biomed Pharmacother. 2023. PMID: 38006616 Free article. Review.
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Hashemi M, et al. Among authors: zandieh ma. Biomed Pharmacother. 2023 Apr;160:114392. doi: 10.1016/j.biopha.2023.114392. Epub 2023 Feb 15. Biomed Pharmacother. 2023. PMID: 36804123 Free article. Review.
Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.
Rezaee A, Tehrany PM, Tirabadi FJ, Sanadgol N, Karimi AS, Ajdari A, Eydivandi S, Etemad S, Rajabi R, Rahmanian P, Khorrami R, Nabavi N, Aref AR, Fan X, Zou R, Rashidi M, Zandieh MA, Hushmandi K. Rezaee A, et al. Among authors: zandieh ma. Biomed Pharmacother. 2023 Sep;165:115187. doi: 10.1016/j.biopha.2023.115187. Epub 2023 Jul 25. Biomed Pharmacother. 2023. PMID: 37499452 Free article. Review.
Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.
Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M. Hashemi M, et al. Among authors: zandieh ma. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166714. doi: 10.1016/j.bbadis.2023.166714. Epub 2023 Apr 5. Biochim Biophys Acta Mol Basis Dis. 2023. PMID: 37028606 Review.
Multifunctional and theranostic hydrogels for wound healing acceleration: An emphasis on diabetic-related chronic wounds.
Tehrany PM, Rahmanian P, Rezaee A, Ranjbarpazuki G, Sohrabi Fard F, Asadollah Salmanpour Y, Zandieh MA, Ranjbarpazuki A, Asghari S, Javani N, Nabavi N, Aref AR, Hashemi M, Rashidi M, Taheriazam A, Motahari A, Hushmandi K. Tehrany PM, et al. Among authors: zandieh ma. Environ Res. 2023 Dec 1;238(Pt 1):117087. doi: 10.1016/j.envres.2023.117087. Epub 2023 Sep 15. Environ Res. 2023. PMID: 37716390 Review.
26 results